Cyclacel Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cyclacel Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Cyclacel Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$1.96M, a 67.6% increase year-over-year.
  • Cyclacel Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$13.4M, a 45.6% increase year-over-year.
  • Cyclacel Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$22.6M, a 6.4% decline from 2022.
  • Cyclacel Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$21.2M, a 14.9% decline from 2021.
  • Cyclacel Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$18.5M, a 119% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$13.4M -$1.96M +$4.08M +67.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$17.5M -$3.26M +$2.19M +40.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$19.7M -$2.95M +$2.86M +49.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$22.6M -$5.27M +$2.15M +29% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$24.7M -$6.03M -$936K -18.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$23.8M -$5.45M -$873K -19.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$22.9M -$5.8M -$1.7M -41.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$21.2M -$7.42M -$2.32M -45.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$18.9M -$5.1M -$339K -7.13% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-29
Q2 2022 -$18.5M -$4.58M +$552K +10.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-29
Q1 2022 -$19.1M -$4.11M -$630K -18.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-29
Q4 2021 -$18.5M -$5.1M -$2.29M -81.8% Oct 1, 2021 Dec 31, 2021 10-K/A 2023-11-29
Q3 2021 -$16.2M -$4.76M -$2.5M -111% Jul 1, 2021 Sep 30, 2021 10-K/A 2023-11-29
Q2 2021 -$13.7M -$5.13M -$2.96M -137% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$10.7M -$3.48M -$2.26M -185% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$8.45M -$2.8M -$499K -21.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 -$7.95M -$2.26M -$355K -18.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$7.59M -$2.17M -$383K -21.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 -$7.21M -$1.22M +$622K +33.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 -$7.83M -$2.3M -$285K -14.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$7.55M -$1.9M +$167K +8.08% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$7.71M -$1.78M +$70K +3.78% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$7.78M -$1.84M -$494K -36.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
Q4 2018 -$7.29M -$2.02M -$148K -7.91% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-05
Q3 2018 -$7.14M -$2.07M -$211K -11.4% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$6.93M -$1.85M +$334K +15.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-13
Q1 2018 -$7.26M -$1.35M +$207K +13.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-13
Q4 2017 -$7.47M -$1.87M +$968K +34.1% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-28
Q3 2017 -$8.44M -$1.86M +$1.09M +37% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$9.53M -$2.19M +$778K +26.2% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$10.3M -$1.56M +$1.49M +48.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 -$11.8M -$2.84M +$535K +15.9% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-30
Q3 2016 -$12.3M -$2.95M -$237K -8.75% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 -$12.1M -$2.97M +$382K +11.4% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 -$12.5M -$3.04M +$1.87M +38.1% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
Q4 2015 -$14.3M -$3.37M +$1.43M +29.7% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-31
Q3 2015 -$15.8M -$2.71M +$2.2M +44.8% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 -$18M -$3.35M +$1.47M +30.4% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-11
Q1 2015 -$19.4M -$4.91M -$43K -0.88% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-13
Q4 2014 -$19.4M -$4.8M -$1.24M -34.8% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-29
Q3 2014 -$18.1M -$4.91M +$97K +1.94% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 -$18.2M -$4.81M -$6.3M -423% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-12
Q1 2014 -$11.9M -$4.87M -$1.79M -58% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-12
Q4 2013 -$10.2M -$3.56M +$1.21M +25.3% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-31
Q3 2013 -$11.4M -$5M -$3.11M -165% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-12
Q2 2013 -$8.24M $1.49M +$5.07M Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-12
Q1 2013 -$13.3M -$3.08M -$127K -4.3% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-13
Q4 2012 -$13.2M -$4.76M -$1.11M -30.2% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-26
Q3 2012 -$12.1M -$1.89M +$1.56M +45.1% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-14
Q2 2012 -$13.6M -$3.58M -$25K -0.7% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-14
Q1 2012 -$13.6M -$2.96M +$1.63M +35.6% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-13
Q4 2011 -$15.2M -$3.66M Oct 1, 2011 Dec 31, 2011 10-K 2014-03-26
Q3 2011 -$3.45M +$362K +9.51% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-16
Q2 2011 -$3.55M +$381K +9.69% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-14
Q1 2011 -$4.59M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-15
Q3 2010 -$3.81M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 -$3.93M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.